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Abstract
The medicinal benefit of salts of fumaric acid and its esters (FAE), known as 
fumarates (mono and dimethyl fumarate), was realized many years ago. Early 
on, FAE were derived from plants and mushrooms (e.g., Fumaria officinalis, 
Boletus fomentarius var. pseudo-igniarius). The FAE containing formulation 
Fumaderm® was licensed in Germany for the treatment of psoriasis in 1994. 
Recently, a clinical formulation of dimethyl fumarate known as BG12 (Tecfidera) 
was approved for use in the United States, New Zealand, Australia, European 
Union, Switzerland, and Canada for the treatment of multiple sclerosis. Others 
and we have assessed the potential benefit of FAE in a number of disease condi-
tions that are diverse with respect to etiology but unified with regard to the 
involvement of inflammation and oxidative stress. Hence, a FAE-based drug 
with robust anti-oxidative and anti-inflammatory effects that is already US-FDA 
approved is a perfect contender for repurposing and rapid clinical implementa-
tion for their management. There is a burgeoning literature on the use of FAE in 
the prevention and treatment of diseases, other than psoriasis and MS, in which 
oxidative stress and/or inflammation are prominent. This chapter highlights 
critical information gleaned from these studies, exposes lacunae of potential 
importance, and provides related perspectives.
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1. Introduction
The salts of fumaric acid (known as fumarates) occur naturally in some plants 
(Fumaria officinalis) and mushrooms. Traditionally, aerial parts of Fumaria offi-
cinalis (common fumitory, drug fumitory or earth smoke) have been utilized for 
the treatment of various skin diseases [1]. Because of its utilization as an herbal 
remedy for skin ailments, German chemist W. Schweckendiek, who was suffering 
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from psoriasis, developed an interest in and isolated fumaric acid esters (FAE) from 
the plant extract. Excited about the positive effects of the FAE mixture on his own 
psoriatic lesions, he began offering it also to other psoriasis patients. Schweckendiek 
later published his findings on the beneficial effects of FAE in psoriasis [2], effects 
that he believed to be attributed to the improvements of this fumarate therapy on 
dysregulation of the citric acid cycle, the potential underlying cause of psoriasis. 
Nonetheless, with advancements in the understanding of psoriasis, his hypothesis 
was found to be incorrect. However, his preliminary observations laid the founda-
tion for the successful development of a drug to treat psoriasis and interestingly, 
multiple sclerosis.
In 1994, some three decades following Schweckendiek’s initial report, a 
fumaric acid mixture composed in large (60%) of dimethyl fumarate (DMF) 
and ethyl hydrogen fumarates was authorized for the treatment of psoriasis 
in Germany under the brand name Fumaderm® [3]. In the clinical setting, 
Fumaderm® proved effective against moderate to severe forms of psoriasis. To 
date, it remains to be the most widely used oral compound for psoriasis therapy 
in Germany. However, Fumaderm® was not licensed and currently remains 
unlicensed for use in the UK and US [4]. Despite this, results establishing DMF 
to be the major active principle in the Fumaderm® led to numerous clinical 
and experimental studies worldwide on the immunomodulatory potential of 
Fumaderm® and DMF in other immune-mediated diseases [5, 6]. The extremely 
positive results that emanated from these studies led to DMF being tested clini-
cally for the treatment of relapsing-remitting multiple sclerosis (RRMS). Like 
the original discovery of FAEs, the exploratory clinical trial of FAE for MS was 
performed in Germany [7]. In this trial, Fumaderm® was given to 10 patients 
with highly active RRMS; six patients completed the 70-week trial. Magnetic 
resonance imaging (MRI)-based results showed that Fumaderm® significantly 
reduced the number of gadolinium-enhanced lesions as well as lesion volumes 
without further worsening of any clinical parameters [7]. Although the overall 
safety profile of Fumaderm® was found to be favorable in this study, the associ-
ated unwanted gastrointestinal discomforts were a major concern. Although this 
initial study was a small, single-center, MRI-based and open-label clinical trial, it 
set the stage for a number of subsequent MS trials with DMF.
After Fumaderm® was licensed to be used in Germany, efforts to develop an 
improved formulation with better tolerability began. This culminated ultimately 
in the introduction of BG12 (brand name Tecfidera) a modified FAE formulation 
[8–10]. Indeed BG-12, comprised only of DMF made available in enteric-coated 
micro tablets, showed better gastrointestinal tolerability compared to Fumaderm® 
and following several clinical trials, this gastro-resistant, delayed-release formula-
tion of DMF was ultimately approved for use in the United States, New Zealand and 
Australia for the treatment of relapsing forms and relapsing MS, respectively, and 
in the European Union, Switzerland and Canada for the treatment of RRMS [11]. 
A plethora of additional information exists on the use of DMF in the treatment of 
MS and psoriasis. For further reading on DMF and MS, please refer to the following 
referenced excellent reviews [12–17].
Drug repurposing is a highly appreciated strategy in the pharmaceutical indus-
try [18]. The fact that agents have been previously tested prior testing of in humans 
and therefore a wealth of detailed information is already available regarding phar-
macology, formulation and safety profile is a huge advantage! Such new candidate 
therapies can often be fast-tracked for clinical trials and related approval by the 
U.S. Food and Drug Administration. There is a burgeoning literature on the use 
of FAE in the prevention and treatment of diseases, other than psoriasis and MS, 
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in which oxidative stress and/or inflammation are prominent. The present review 
highlights critical information gleaned from these studies and exposes and provides 
perspectives on lacunae of potential importance.
2. Pharmacokinetics of fumaric acid esters
Dimethyl fumarate (PubChem CID: 637568), described as a “white crystalline 
compound with a fruit-like taste” [19], is a dimethyl ester of fumaric acid with 
the official chemical name of trans-1,2-ethylene carboxylic acid dimethyl ester 
[20]. Because of its rapid degradation by intestinal esterase, DMF does not cross 
the intestinal wall in significant amounts [21]. Thus, because of its short-lived 
activity, evidence of direct, sustained anti-inflammatory or antioxidant effects 
derived directly from DMF is limited [22]. Instead, monomethyl fumarate (MMF; 
PubChem CID: 21721168), the product of DMF metabolism by intestinal esterase, 
is said to be the main active metabolite [23]. This is confirmed by pharmacoki-
netic studies that demonstrate following oral DMF intake, serum concentrations 
of MMF peak within 2–2.5 h and its half-life is approximately 1 h [24]. Further, 
the ingestion of DMF along with a high fat/high-calorie diet was found to inter-
fere with intestinal absorption, delaying the systemic peak of MMF significantly 
[16, 17]. Following doses of delayed-release DMF of up to 240 mg, the mean Cmax 
of MMF in healthy human subjects was 1.43 μg/ml with a corresponding MMF 
area under the curve of 2.41 μg h/ml. There was no evidence of accumulation after 
multiple doses (e.g. 240 mg delayed-release DMF three times daily for 2 days) 
as MMF concentrations fell below detectable limits at the end of day 1 and day 
2 [24]. MMF is eliminated primarily through breathing; negligible amounts of 
intact MMF are excreted through urine or feces. Additionally, there is no evidence 
of cytochrome P450-dependent metabolism of the compound in the liver [25]. 
Because of the lack of cytochrome P 450 involvement, DMF has very limited 
drug–drug interactions. Congruent with the above, both DMF and MMF have 
been popularly used for various pre-clinical pharmacological studies aimed at the 
testing and development of new therapeutics for various indications. The intesti-
nal metabolism of DMF and diroximel fumarate (DRF), two current clinical FAE 
formulations is shown in Figure 1.
Figure 1. 
Metabolism of fumaric acid esters. Clinical formulations of FAE are composed of dimethyl fumarate (DMF) or 
diroximel fumarate (DRF). Following oral administration, intestinal esterase metabolizes both DMF and DRF 
into the major bioactive ingredient MMF (monomethyl fumarate). Methanol, hydroxyethyl succinimide (HES) 
and RDC-8439 are also produced but only as minor metabolites (< 10%).
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3. Mechanism of action: fumaric acid esters
Despite the numerous in vitro and in vivo studies that have been conducted 
over the years, the mechanism of action of FAE is still not fully understood and 
novel aspects continue to emerge. The generic hypothesis to explain the benefits 
of FAE is that DMF/MMF interferes with the cellular redox system by inducing a 
strong antioxidant response. Indeed, the robust induction of Nrf2 (nuclear factor 
E2 (erythroid-derived 2)-related factor) by DMF/MMF has been well described 
(Figure 2). In cells, DMF/MMF leads to the nuclear translocation of Nrf2, a phe-
nomenon that is known to in turn, enhance the expression of antioxidant enzymes 
[26]. Specifically, it has been shown that MMF induces alkylation of a critical reac-
tive thiol, Cys151, on Keap1 (Kelch-like ECH associated protein 1) which results in 
the release of Nrf2 [26, 27]. Once dissociated from Keap-1, Nrf2 translocates to the 
Figure 2. 
Involvement of Nrf2-dependent and independent mechanisms in FAE-mediated antioxidant and anti-
inflammatory effects. Fumaric acid esters (DMF/MMF) disrupt Keap1-Nrf2 binding to induce nuclear 
translocation of Nrf2 which in turn, activates a number of downstream antioxidant response genes. This 
mode of action of FAE is well known and is purported to be responsible for the positive actions of FAE in 
neurotoxicity, nephrotoxicity, and spinal cord injury. Additionally, however, MMF, the major bioactive 
ingredient of FAE, is an agonist of HCAR2, a Gi-protein coupled membrane receptor that potentiates robust 
anti-inflammatory signaling. Various studies have shown that while FAE-mediated Nrf2 signaling elicits 
both antioxidant and anti-inflammatory responses, HCAR2-dependent signaling predominantly provides an 
anti-inflammatory effect. The HCAR2-mediated actions of FAE have been implicated its protective effects 
in gastrointestinal diseases, pancreatitis and neuroinflammation. Importantly however, the combined actions 
(Nrf2- and HCAR2-mediated) have been demonstrated in several pathologic conditions (sickle cell disease, 
retinal degeneration, sepsis and stroke). FAE, fumaric acid esters; HCAR2 or HCA2, hydroxycarboxylic acid 
receptor 2; DMF, dimethyl fumarate; MMF, monomethyl fumarate; Keap1; kelch-like ECH associated protein 
1; Nrf2, nuclear factor erythroid 2-related factor 2; ARE; antioxidant responsive element.
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nucleus and therein, binds to the antioxidant response element (ARE) of an array of 
antioxidant target genes thereby upregulating their expression and related activity. 
This effect was corroborated in Nrf2-deficient cells in which the antioxidant effects 
of DMF/MMF were lost [27].
The majority of preclinical studies of DMF/MMF, highlight the Nrf2-mediated 
mechanism of the drug as the principal factor underlying its therapeutic effects. 
However, DMF/MMF has also been shown to elicit a robust anti-inflammatory 
response. This additional desirable effect is thought to be accomplished via the 
inhibition of NF-kB translocation into the nucleus, an action that impacts nega-
tively the expression of a plethora of inflammatory cytokine, chemokine, and 
adhesion molecule genes. Relevant also to the anti-inflammatory effects of DMF/
MMF, is hydroxycarboxylic acid receptor 2 (HCAR2; GPR109A)-dependent signal-
ing (Figure 2). MMF is a strong agonist of HCAR2. DMF activates the receptor as 
well although with a comparably lower affinity [28]. In a study by Chen et al. 2014 
it was shown that DMF treatment reduced pathological features of experimental 
autoimmune encephalomyelitis in WT mice, but not in Hcar2−/− mice, indicating 
the importance of HCAR2-mediated signaling by DMF [29]. In another study, 
Parodi et al. [30] demonstrated the importance of HCAR2 to the anti-inflammatory 
effects of MMF in microglia. Specifically, it was reported that MMF could modulate 
microglia activation through inhibition of the NF-κB pathway via the AMPK/SIRT-1 
axis. MMF treatment to microglia cells resulted in the activation of the HCAR2 
receptor via enhanced intracellular calcium levels, an effect that prevents microglial 
polarization into an inflammatory phenotype (Figure 3). Downstream, it induced 
CAMKK (Calcium/calmodulin-dependent protein kinase kinase 2) dependent 
activation of AMPK/SIRT-1 axis which also contributes to reduced inflammation. 
Several other studies have also reported on the HCAR2 receptor-dependent and 
independent anti-inflammatory effects of FAE in additional cell types including 
keratinocytes [31–33] and epithelial cells of the retina [34, 35].
4. Role of FAE in inflammatory and oxidative stress conditions
Herein we highlight the findings of preclinical studies on the use of DMF/MMF 
to counter inflammation and oxidative stress associated with the pathogenesis of 
pathological conditions other than psoriasis and MS (Figure 2). A summary is 
provided in Table 1.
Figure 3. 
The role of FAE in regulating microglia activation. FAE (DMF/MMF) are known to induce Nrf2 and to 
activate HCAR2. Various studies have shown that via these mechanisms, FAE prevent the polarization of 
microglia from the M1 (resting) phenotype to the M2 (active and thereby pro-inflammatory) phenotype, 
the consequences of which are reduced free radical and pro-inflammatory cytokine production. This 
action of FAE is thought to underlie the neuroprotective effects of the drug in conditions like HIV-induced 
neuroinflammation, Parkinson’s disease, retinal degeneration, and stroke. FAE, fumaric acid esters, HCAR2, 
hydroxycarboxylic acid receptor 2; DMF, dimethyl fumarate; MMF, monomethyl fumarate; Nrf2, nuclear 
factor erythroid 2-related factor 2; HIV, human immunodeficiency virus.
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Disease 
condition
Experimental 
model
Effective dose Outcomes References
Cerebral 
ischemia–
Middle cerebral 
artery occlusion 
in rats
25 and 50 mg/
kg DMF (i.g.)
DMF protected against 
experimental stroke by inducing 
immunomodulatory and 
antioxidant response
[91]
Middle cerebral 
artery occlusion 
in mice
30 and 45 mg/
kg DMF and 
MMF (i.p.)
DMF and MMF suppressed glial 
activation via increasing the 
expression of Nrf2
[92]
Experimental 
colitis
a. Mice treated 
with DNBS.
b. IL-10−/− mice.
30 and 
100 mg/kg 
DMF (i.g.)
DMF induced antioxidant 
response by regulating SOD-2 
and inflammation by Nf-kB 
signaling to reduce colitis.
[40]
Mice treated with 
3% (w/v) DSS 
drinking water
30 and 60 mg/
kg DMF (i.g.)
DMF alleviated DSS-induced 
colitis by regulating Nrf2-
mediated inhibition of NLRP3 
inflammasome
[41]
Intracerebral 
hemorrhage
Intra-striatal 
injection of 
autologous blood 
in rats and mice
15 mg/kg 
DMF (i.g.)
DMF can ameliorate ICH-
mediated injury with a 
therapeutic window of at least 
24 h
[87]
Mice using either 
the collagenase 
injection model 
(cICH) or the 
autologous blood 
(bICH)
100 mg/kg 
(i.p.)
DMF-induced dissociation 
of Nrf2 from Keap1, and the 
consequent casein kinase 2 
phosphorylation of Nrf2, resulted 
in neuroprotection after ICH
[88]
Nephrotoxicity Rats treated 
with 20 mg/kg 
Cyclosporin A for 
28 days
50 mg / kg 
DMF (i.g.)
DMF reduced nephrotoxicity by 
inhibiting oxidative stress and 
inflammation
[53]
Neurotoxicity Mice treated with 
10 nmol sodium
nitroprusside
60 and 
200 mg/kg 
DMF (i.g.)
DMF reduced neurotoxicity by 
activating HO-1.
[54]
Pancreatitis Rats treated  
with 2.5 g/
kg L-arginine
25 mg/kg 
DMF (i.g.)
DMF was effective in 
ameliorating the histological 
lesions and biochemical 
abnormalities and improving 
beta-cell function
[59, 60]
Rats treated with 
3 g/Kg L-arginine
25 mg/Kg 
DMF (i.g.)
DMF treated rats showed 
reductions in the severity of 
inflammatory cell infiltration, 
acinar damage, perilobar edema, 
and cell necrosis
[61]
Parkinson’s 
disease
6-OHDA-induced 
neurotoxicity in 
mice
50 mg/kg 
DMF (i.g.)
DMF reduced neurotoxicity 
by Nrf2 mediated antioxidant 
response.
[66]
Mice treated with 
MPTP
100 mg/kg 
MMF/
DMF (i.g.)
DMF and MMF exhibit 
neuroprotective effects via 
Nrf2-mediated antioxidant, anti-
inflammatory, and mitochondrial 
functional/biogenetic effects.
[67]
Mice treated with 
a viral vector 
expressing human 
α-SYN
100 and 
300 mg/kg 
DMF (i.g.)
DMF prevented Synucleinopathy 
in a mouse model of PD by 
activating Nrf2 signaling
[69]
MPTP-treated 
mice
10, 30, and 
100 mg/kg 
DMF (i.g.)
DMF protected against 
experimental PD via regulation 
of the NF-κB/Nrf-2 pathway
[70]
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4.1 Gastrointestinal diseases
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the 
colon and small intestine that includes Crohn’s disease and ulcerative colitis [36, 37]. 
Treatments for IBD range from symptomatic treatment with anti-diarrheal medica-
tions, anti-inflammatory agents or immunosuppressive drugs to more radical surgical 
interventive strategies (e.g. partial or complete colectomy). These strategies are effec-
tive in a number of patients however given the complex etiology of IBD, the need for 
new and/or improved therapeutic strategies remains high. Given the well-established 
link between inflammation and IBD development and progression, it is not surprising 
that several groups have sought to test the efficacy of FAE in this condition. For the 
most part, these studies have been conducted using experimental models of colitis; 
rodents treated with dinitrobenzene sulfuric acid (DNBS) or dextran sodium sulfate 
(DSS), etc. [38, 39]. Casili et al. induced colitis in mice via intrarectal administration 
of DNBS (4 mg/mouse). DMF (10, 30 or 100 mg/kg) was then administered orally 
Disease 
condition
Experimental 
model
Effective dose Outcomes References
Retinal
degeneration
I/R injury in mice 50 mg/kg 
MMF (i.p.)
MMF reduced retinal I/R  
injury in mice via induction  
of Nrf2 signaling
[73]
Light-induced 
retinal damage in 
mice
100 mg/kg 
MMF (i.p.)
MMF-mediated HCAR2 signaling 
provided neuroprotection via 
reduced microglial activation, 
inflammation, and oxidative 
stress.
[75]
Sepsis Rats subjected 
to cecal ligation 
and puncture 
procedure
15 mg/kg of 
DMF (i.g.)
DMF reduced inflammation and 
oxidative stress in heart, liver, 
lung, kidney, and brain,
and improved cognitive function
[77, 78]
50 mg/kg 
MMF (i.p.)
MMF alleviated sepsis-induced 
hepatic dysfunction by reducing 
oxidative and inflammatory via 
the inhibition of the TLR-4/
NF-κB signaling pathway.
[79]
Sickle cell 
disease
HbSS-Townes and 
NY1DD mice
30 mg/kg 
DMF (i.g.)
DMF increased expression of 
nuclear Nrf2 in the liver and 
kidney to decreases oxidative 
stress and inflammation
[83]
Sickle cell 
retinopathy
HbSS-Townes 
mice
1 mM 
(intravitreal) 
and 15 mg/
ml MMF 
(in drinking 
water)
MMF treatment-induced fetal 
hemoglobin production and 
reduced oxidative stress and 
inflammation via Nrf2 activation
[34, 35]
Spinal cord 
injury
SCI injury in mice 
using aneurysm 
clip
30 mg/kg 
(i.g.)
DMF and MMF improved SCI 
injury in mice.
[86]
Ulcer Rats exposed 
to chronic foot-
shock stress
2.5 and 5 mg/
kg MMF (i.p.)
MMF restored monoamine, 
corticosterone, and cytokine 
homeostasis by regulating 
neuroendocrine-immune systems
[41]
Table 1. 
Some important in vivo studies showing the use of fumaric acid esters for the treatment of oxidative stress and 
inflammation.
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every 24 h, starting 3 h after the administration of DNBS and continuing over the 
course of 4 days. DMF treatment to DNBS treated mice significantly improved colon 
injury and histological score. Further DMF also reduced lipid peroxidation by regu-
lating the expression of SOD2 (superoxide dismutase 2, mitochondrial) and Nrf2. 
The anti-inflammatory effect of DMF was evident by a reduction in the expression of 
TNF-α (tumor necrosis factor- α), IL-1β (Interleukin 1 beta) and ICAM-1 (intercel-
lular adhesion molecule 1) and P- selectin. This effect was thought to be a result of 
reduced IκB-α degradation to prevent nuclear translocation of p65 NF-κB (Nuclear 
factor-κB). Moreover, in vitro DMF treatment improved hydrogen peroxide-induced 
barrier dysfunction of human intestinal epithelial cells. The authors also confirmed 
the protective effect of DMF on experimental colitis using another model (9-week-
old IL-10KO mice). Collectively, this study demonstrated that DMF could reduce 
experimental colitis by regulating inflammation and oxidative stress [40]. In another 
study, Liu et al., 2016 evaluated the efficacy of DMF in reducing DSS-induced 
murine colitis. Wild-type and Nrf2−/− mice received either vehicle or 3% (w/v) DSS 
in drinking water for 7 days and thereafter provided with only drinking water for 
another 3 days. Groups of mice were also given 30 or 60 mg/kg DMF (i.g.) from day 
1 to 10. DMF treatment significantly reduced oxidative stress and inflammation and 
thereby improved signs/symptoms of colitis in DSS-treated mice. However, these 
effects were lost in Nrf2−/− mice, highlighting the importance of the Nrf2-mediated 
mechanism of action of the drug. This was supported by additional in vitro studies in 
which the authors showed that DMF-mediated Nrf2 activation reduces NLRP3 (NLR 
family pyrin domain containing 3) inflammasome activation to control intestinal 
inflammation.
Consistent with the above gastrointestinal benefits derived from DMF/MMF 
treatment, the efficacy of MMF treatment in improving stomach ulcers in rats has 
also been described. Although the detailed mechanism of action was not evaluated, 
the authors attributed the protective effect of the compound in this condition to be 
due primarily to the anti-inflammatory activity of MMF [41]. Collectively, these 
studies indicate that DMF/MMF therapy may be of benefit the clinical management 
of inflammatory gastrointestinal disorders. This is interesting given that gastroin-
testinal (GI) side effects (e.g., nausea, vomiting, diarrhea, and upper abdominal 
pain) are one of the most commonly reported complaints in patients receiving DMF 
therapy [42, 43]. Indeed, during phase 3 clinical trials for multiple sclerosis, adverse 
events (AEs) involving the GI system were reported in 40% of patients treated with 
DMF compared with 30% of patients treated with placebo [44, 45]. Though the 
adverse GI events are generally mild in severity and typically resolve within the first 
2 months of treatment, these issues may impact patient quality of life and ulti-
mately medication adherence. Thus, while a number of experimental studies have 
reported gastroprotective effects of DMF, there is some concern as to whether such 
therapy could reliably be extrapolated to clinical management of gastrointestinal 
disorders in human patients. However, the increasing number of additional reports 
of DMF/MMF benefit in the digestive system that continue to arise in the scientific 
literature suggests that perhaps efforts to implement DMF/MMF therapy for use 
in this regard should not be dismissed completely. For example, Rao and Mishra 
[46] performed a preliminary study demonstrating the hepatoprotective effects 
of MMF isolated from Fumaria Indica extract in various models of hepatotoxicity. 
Although the study was preliminary and had some limitations, it does introduce a 
possible hepatoprotective effect of MMF. This is supported also by a recent study 
by Abdelrahman et al. [47] that reported the protective effects of DMF treatment 
on acetaminophen-induced hepatic injury in mice. Acetaminophen-treated mice 
receiving a single or double dose of DMF (100 mg/kg) showed reduced oxidative 
stress, inflammation, and associated liver damage compared to non-DMF treated 
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animals. Hence, additional studies in larger animal models and at some point, 
in humans, to test, develop and/or refine DMF/MMF formulations to improve 
potential suitability for use in the treatment of gastrointestinal or liver diseases are 
warranted.
4.2 HIV-induced neuroinflammation and neurotoxicity
With improvements in treatments for HIV (human immunodeficiency virus), 
lifespan has increased significantly affected persons. However, neuroinflamma-
tion and/or toxicity remain major concerns in this disease. The critical relevance of 
neuroinflammation to the etiology of MS, a disease for which DMF/MMF therapy is 
already approved, is undeniable [48]. Further, patients with MS are at considerably 
higher risk for neurotoxicity than are patients without the demyelinating disease 
[49]. Given these commonalities between MS and HIV-induced neurologic disease, 
preclinical testing of DMF/MMF in the latter is of interest. Using an in vitro model 
of HIV-mediated neurotoxicity, Cross et al. 2011 [50] showed that HIV infection 
dysregulates macrophage antioxidant response and reduces the expression of heme 
oxygenase-1 (HO-1). Importantly, DMF and MMF (5–30 μM) dose-dependently 
suppressed HIV replication, improved antioxidant response and reduced neuro-
toxin release, effects that the authors proposed to be mediated via a two-way action 
of DMF: (1) inhibition of NF-kB nuclear translocation and consequent suppression 
of HIV replication, and (2) decreased neurotoxin release stemming from HO-1 
induction. Further, they also found that DMF reduces CCL2 (C-C Motif Chemokine 
Ligand 2)-induced monocyte chemotaxis, suggesting that DMF additionally 
decreased the recruitment of activated monocytes to the CNS (central nervous sys-
tem) in response to inflammatory mediators. Based on the above, the authors con-
cluded that dysregulation of the antioxidant response during HIV infection drives 
macrophage-mediated neurotoxicity and DMF could serve as an adjunctive neuro-
protectant. In a separate study, Ambrosius et al. [51] evaluated the effect of MMF 
on microglia activation and subsequent neurotoxicity. MMF treatment (10–30 μM) 
significantly reduced HIV-mediated neurotoxicity in microglia cells (Figure 3). A 
similar but prior study by a different group showed MMF to be capable of inducing 
a phenotypic shift from pro-inflammatory to anti-inflammatory macrophages [52] 
however, Ambrosius et al. did not observe such effects. These differences could be 
model-dependent or related to methodological differences in the two studies and 
therefore require further investigation since the authors did not comprehensively 
evaluate the possible mechanism of action in these short reports. Notwithstanding, 
however, the opposing effects of DMF/MMF on microglial responses, particularly 
those of an inflammatory nature, appear to be solidly supported by several other 
studies [30] which in turn, collectively support additional effort to advance DMF/
MMF therapy for potential use in HIV-associated neuroinflammation and toxicity.
4.3 Nephrotoxicity
Very little information exists on the protective effect of FAEs on renal func-
tion. A study by Takasu et al. [53] evaluated the effect of DMF treatment on CsA 
(calcineurin inhibitor)-induced nephrotoxicity. Male Sprague–Dawley rats were 
treated with 20 mg/kg CsA or CsA + 50 mg/kg DMF (i.g.) for 28 days. At the end of 
the treatment schedule, renal function, histopathology, malondialdehyde (MDA), 
myeloperoxidase levels, and antioxidant enzyme expression were determined. 
DMF co-treatment ameliorated CsA-induced renal dysfunction as evidenced by 
a significant decrease in serum creatinine and urea levels, as well as improvement 
of creatinine clearance. DMF also significantly decreased serum and renal MDA 
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and myeloperoxidase contents whereas, protein expression of NQO-1 (NAD (P) 
H quinone oxidoreductase-1), a major cellular antioxidant and the detoxifying 
enzyme, was significantly enhanced by DMF administration. Although evidence 
is limited, the above study supports the protective potential of DMF/MMF therapy 
in a clinically relevant model of nephrotoxicity, an effect that is afforded in part 
via DMF’s robust ability to enhance the cellular antioxidant capacity and thereby, 
inhibit oxidative stress and inflammation [53] as described in other cell and tissue 
systems. Thus, while much remains to be learned about the possible use of DMF/
MMF in the treatment of renal diseases, initial results are encouraging.
4.4 Non-HIV related neurotoxicity
Prior discussion (subSection 4.2) of neurotoxicity in this chapter was related 
specifically to that occurring in HIV. Irrespective, however, of the mitigating disease 
or pathologic process, the brain is indisputably sensitive to pro-inflammatory 
and/or oxidative insult. Hence, neurotoxicity can emanate from multiple variable 
causes. Kume et al. [54] evaluated the ability of DMF to protect against in vitro 
and in vivo oxidative stress in the central nervous system induced via pro-oxidant 
agents like sodium nitroprusside and hydrogen peroxide (H2O2). DMF pretreat-
ment (60–200 mg/kg) for 24 h dose-dependently protected against 10 nM sodium 
nitroprusside-induced brain damage and in rat primary striatal cell cultures, 10 μM 
DMF markedly prevented cytotoxicity stemming from exposure of cells to H2O2 
(1 mM). Interestingly, the protective effects of DMF against in vitro oxidative stress 
were countered by the HO-1 inhibitor zinc protoporphyrin IX however, buthionine 
sulfoximine, an inhibitor of glutathione synthesis, did not interfere with the protec-
tion afforded by DMF. Collectively, these results support the potential of DMF/
MMF therapy in conditions of neurotoxicity and suggest that its ability to activate 
HO-1 may be critical. Neural stem/progenitor cells (NPCs) are a heterogeneous 
population of self-renewing and multi-potent cells that can differentiate into neu-
rons, astrocytes, or oligodendrocytes (post-mitotic daughter cells) [55, 56]. Hence, 
the survival of these cells could greatly impact various forms of neurodegenerative 
diseases. Wang et al. [57] reported on the neuroprotective effects of DMF on mouse 
and rat neural stem/progenitor cells (NPCs) and neurons. DMF treatment reduced 
reactive oxygen species (ROS) production, increased the frequency of the multi-
potent neurospheres and enhanced the survival of NPCs following H2O2-mediated 
oxidative stress. DMF also decreased oxidative stress-induced apoptosis and 
promoted the survival of motor neurons, effects that this group demonstrated to 
be mediated via the Nrf2-ERK1/2 MAPK pathway. These studies provide additional 
support of the overwhelmingly protective effects of FAE in multiple brain cell types 
and therefore, of the potential feasibility of this therapy in the prevention and treat-
ment of neurodegenerative diseases.
4.5 Pancreatitis
Chronic pancreatitis (CP) is a progressive inflammatory disorder that results in 
the destruction and fibrosis of the pancreatic parenchyma and its endocrine and 
exocrine dysfunctions [58]. Various research groups have evaluated the effect of 
DMF treatment on acute and chronic pancreatitis. In one of the studies, chronic 
pancreatitis in rats was induced by five injections of 250 mg/100 g L-Arginine and 
sacrificed 7 weeks later. In another group 25 mg/kg DMF was given orally 24 before 
L-arginine treatment and continued thereafter until the end of the study. DMF 
treatment significantly improved glucose tolerance, pancreas histology, biochemical 
parameters (MDA and MPO; myeloperoxidase), and induced HO-1 expression [59]. 
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However, this study did not evaluate the mechanism of action for DMF-induced 
protection. Another study by Robles et al. [60] evaluated the efficacy of DMF in 
an acute model of pancreatitis. Acute pancreatitis was induced by two injections 
of 3 g/kg L-Arginine (1 hr. apart) to rats and sacrificed later at 24 and 72 hr. DMF 
(25 mg/kg) was orally administered to rats 24 h before L-arginine and continued 
until sacrifice. The histology of the pancreas was significantly improved in DMF-
treated animals possibly due to decreased cleaved caspase-3 (apoptosis) and MDA 
levels. This group additionally stimulated splenocytes with 1 μg/ml for 24 h with 
or without DMF 20 μM. In vitro DMF treatment significantly reduced proinflam-
matory cytokine secretion in rat splenocytes, although a definitive mechanism for 
this DMF-mediated action was not put forward. Recently, however, Zhang and 
colleagues [61] too evaluated the effect of DMF on L-arginine induced chronic 
pancreatitis. In brief, this group treated Wistar rats intraperitoneally with L-arginine 
5 times (250 mg/100 kg, twice per time, each interval of 1 h) to induce chronic 
pancreatitis (CP). One group of rats was treated with 20 mg/kg DMF. Compared 
with control (untreated) group, the weight of rats in CP group was significantly 
reduced at weeks 2, 4 and 6; blood glucose levels were significantly increased, the 
histopathological scores of pancreatic atrophy, acinar injury, edema, and cellular 
infiltration increased, levels of MDA and MPO increased, and the islet equivalent 
and islet activity decreased at 0, 30, 60, 120 and 180 min., parameters that were 
all prevented or reversed in the DMF-treated CP group. Thus, DMF treatment can 
protect against CP induced by L-arginine and islet function in rats. Although these 
three studies support the potential of DMF/MMF therapy in pancreatitis, the exact 
mechanism (s) to explain the benefits attained remains unknown. Because therapies 
to impact pancreatitis are extremely limited at present, additional detailed studies to 
test the efficacy of FAE in this condition would certainly be worthwhile in hopes that 
findings emanating therefrom could be carried forward to use in a clinical setting.
4.6 Parkinson’s disease
Again, the brain is especially sensitive to perturbations caused by oxidative 
and/or inflammatory stress. In fact, these factors, particularly oxidative stress, 
are central to the pathology of several neurodegenerative diseases, including 
Parkinson’s disease (PD) [62, 63] therefore, therapies designed to enhance antioxi-
dant potential and counter this stress may be of clinical value [64, 65]. Scientific 
studies published within the last couple of years highlight the high clinical potential 
the repurposing of DMF/MMF for the treatment of PD holds. Using various in vitro 
and in vivo studies it has been demonstrated that DMF/MMF induced Nrf2 signal-
ing can protect against oxidative stress and inflammatory conditions related to 
PD. In an initial study by Jing et al. [66], DMF (2–4 μM) pre-treatment significantly 
reduced hydroxydopamine (6-OHDA) induced generation of ROS and subsequent 
cytotoxicity in SH-SY5Y cells. The increase in ROS production caused by 6-OHDA 
treatment was also attenuated by DMF. Further, siNrf2 treatment blocked DMF’s 
protection against 6-OHDA-induced neurotoxicity. In vivo, oral administra-
tion of DMF (50 mg/kg) to C57BL/6 mice up-regulated expression of Nrf2 and 
Nrf2-dependent cytoprotective genes. Taken together, this study provided initial 
evidence for the protective role of DMF in PD. This was followed by three different 
studies focusing on the mechanism of action for DMF and its metabolite, MMF in 
mediated protection against PD. Ahuja et al. [67] compared the effects of DMF and 
MMF on Nrf2 signaling by evaluating its ability to block 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced experimental PD. Their results showed that 
Nrf2 activation by DMF was associated with depletion of glutathione, decreased 
cell viability, and inhibition of mitochondrial oxygen consumption and glycolysis 
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rates in a dose-dependent manner. Contrary to this, MMF increased these activities 
in vitro. However, both DMF and MMF activated the Nrf2 pathway via S-alkylation 
of the Nrf2 inhibitor Keap1 which promoted the nuclear exit of the Nrf2 repres-
sor Bach1 to improve mitochondrial biogenesis. Despite the in vitro differences, 
both DMF and MMF exerted similar neuroprotective effects and blocked MPTP 
neurotoxicity in wild type but not in Nrf2−/− mice. It was concluded that DMF 
and MMF exhibit neuroprotective effects because of their distinct Nrf2-mediated 
antioxidant, anti-inflammatory, and mitochondrial functional/biogenetic effects, 
but MMF does so without depleting glutathione and inhibiting mitochondrial and 
glycolytic functions. Therefore, the authors advocated for the possible develop-
ment of MMF rather than DMF as a novel therapy for PD. Synucleinopathies (also 
called α-synucleinopathies; α-SYN) are neurodegenerative diseases characterized 
by the abnormal accumulation of aggregates of alpha-synuclein protein in neu-
rons, nerve fibers or glial cells [68]. Lastres-Becker et al. [69] conducted a study in 
which they focused primarily on the role of DMF in regulating synucleinopathies 
associated with oxidative stress and inflammation. In brief, an adeno-associated 
pseudotype 6 (rAAV6) viral vector was used to express human α-SYN under 
the neuron-specific human synapsin 1 promoter to create conditions of PD and 
animals were treated daily with DMF (100–300 mg/kg) via oral gavage. DMF 
protected nigral dopaminergic neurons against α-SYN toxicity and decreased 
astrocytosis and microgliosis. However, this protective effect was not observed in 
Nrf2−/− mice. Additionally, in vitro studies indicated that the neuroprotective effect 
was correlated with altered regulation of autophagy markers and with a shift in 
microglial dynamics toward a less pro-inflammatory and a more wound-healing 
phenotype (Figure 3). These experiments provide a compelling rationale for 
targeting Nrf2 with DMF as a therapeutic strategy to reinforce endogenous brain 
defense mechanisms against PD-associated synucleinopathy. These findings are 
supported by another study in which daily oral administration of DMF (10, 30, and 
100 mg/kg) significantly reduced neuronal cell degeneration of the dopaminergic 
tract and behavioral impairments induced by four injections of the dopaminergic 
neurotoxin MPTP. Moreover, treatment with DMF prevented dopamine depletion, 
increased tyrosine hydroxylase, and dopamine transporter activities, and also 
reduced the number of α-synuclein-positive neurons. Furthermore, DMF treat-
ment up-regulated Nrf2 as evidenced by the increased activation of SOD2 and 
HO-1 and elevated levels of glutathione, and increased NeuN+/Nrf2+ cell number 
in the striatum. Moreover, DMF reduced IL-1β levels, cyclooxygenase 2 activities, 
and neuronal nitrite oxide synthase expression. This treatment also modulated 
microglial activation (Figure 3), restored nerve growth factor levels, and preserved 
microtubule-associated protein 2 alterations. Using the Nrf2 inhibitor trigonelline, 
the authors were able to confirm the Nrf2 dependency of the protective mechanism. 
Collectively, these results demonstrated that DMF protects against experimental PD 
via NF-κB/Nrf2 pathway [70]. Several other antioxidants have shown potential as 
therapeutic options for PD, however, because DMF/MMF is already FDA-approved, 
the potential viability of this candidate therapy for PD is enhanced.
4.7 Retinal degenerative diseases
In recent years, others and we have investigated the potential of MMF in the 
treatment of degenerative retinal diseases. In an early study, we showed MMF to be 
protective against reactive gliosis, a characteristic response of Muller glial cells to an 
environment rich in pro-oxidant and inflammatory factors in retinal disease. Folate 
uptake by Muller cells is considered a key event in this process [71]. MMF treatment 
significantly reduced folate uptake by Muller cells by decreasing the expression and 
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activity of proton-coupled folate transporter (PCFT), a transporter integral to the 
uptake of folate. This was the first report demonstrating that MMF could regulate 
folate transport in retinal glial cells and therefore, be potentially useful in the treat-
ment of degenerative retinal diseases. To determine whether, in addition to down-
regulating pro-inflammatory mechanisms, MMF affects counteractive or protective 
signaling, in a subsequent study we evaluated also the effect of the compound on 
the expression and activity of the cysteine/glutamate exchanger SLC7A11 (system 
xc
−), a transport system critical for the intracellular entry of the amino acid cysteine 
which is required for glutathione synthesis [28]. Glutathione is the most abundant 
endogenous antioxidant in the retina and is therefore essential for the protection of 
retinal cells against oxidative stress. Further, retinal pigment epithelial (RPE) cells 
are one of the highest producers of glutathione of any cell type in the body. As such, 
we exposed human retinal pigment epithelial (ARPE-19) cells to MMF in the pres-
ence or absence of pro-oxidant stimuli and evaluated the dose- and time-dependent 
effects on system xc
− mRNA, protein, and activity levels. MMF was found to up-
regulate each of these parameters and additionally, up-regulate hypoxia-inducible 
factor 1-alpha (Hif-1α), nuclear factor erythroid 2-related factor 2 (Nrf2) expres-
sion and increase total reduced glutathione (GSH) content. Collectively, our early in 
vitro studies demonstrated that MMF affects multiple pathways in multiple retinal 
cell types in a manner that is overall protective against oxidative damage.
We sought next to determine whether our findings extrapolate to the in vivo 
condition, therefore, we evaluated the efficacy of MMF in a living animal model 
of retinal disease. Retinopathy is a major cause of vision loss in sickle cell disease 
(SCD) and therapies to prevent and treat sickle retinopathy (SR) are very limited. 
Therapeutic induction of γ-globin expression and subsequent induction of fetal 
hemoglobin (HbF) production can alleviate some SCD-associated complications. 
Interestingly, Nrf2 inducers have been demonstrated to be effective γ-globin induc-
ers [72]. The robust inductive properties of MMF on Nrf2 translocation and activity 
have been long recognized therefore, it was logical to explore the effects of MMF in 
SCD. Not only did we confirm that RPE cells, cells integral to retinal health and func-
tion, produce HbF but that MMF treatment of Townes humanized SCD mice of SCD 
resulted in reductions in the expression of pro-oxidant and inflammatory factors 
and turn, preserved retinal morphology [35]. Shortly after this study, Cho et al. [73] 
too reported on the potential benefit of MMF in the treatment of retinal disease in a 
mouse model of retinal ischemia-reperfusion. Specifically, they showed that MMF 
promotes Nrf2-neuroprotection in this model. MMF treatment was associated with 
significant increases in the expression of Nrf2-responsive antioxidant genes and a 
suppression of inflammatory responses as evidenced by increased expression of NAD 
(P) H quinone dehydrogenase 1, thioredoxin reductase 1 and heme oxygenase-1 
along with decrease in interleukin-1β, chemokine (C-C motif) ligands (2, 7 and 12), 
expressions. Collectively, these molecular improvements interpreted to improved 
retinal function as evidenced by electroretinogram recordings performed on live 
mice and were heavily dependent upon the expression and activity of Nrf2.
Because these initial reports of MMF’s potential efficacy in protecting against 
retinal degeneration were conducted acutely, we decided to evaluate the effect of 
long-term administration of the compound (5 months administration of 15 mg/ml 
MMF in drinking water) in the humanized SCD model [34]. Importantly we found 
via high-pressure liquid chromatography (HPLC) and hematological analyses of 
peripheral blood that MMF treatment reduced sickle hemoglobin (HbS) content and 
white blood cell counts, and improved hematocrit, red blood cell number, and hemo-
globin concentrations significantly in SCD mice. In retina specifically, the mRNA 
and protein expression of well-established markers of inflammation and oxidative 
stress (i.e., vascular endothelial growth factor, intercellular adhesion molecule-1, 
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interleukin-1β, dihydroethidium labeling) was reduced and the development and 
progression of SCD-like retinal pathology in these mice were ameliorated. Additional 
related in vitro studies performed toward elucidating the molecular mechanisms 
responsible for the MMF-induced improvements that were observed implicate Nrf2 
and Bcl11A (B-cell lymphoma/leukemia 11A) as key players. This study was of 
extreme significance because not only did it support strongly the notion that fumaric 
acid ester therapy may be of benefit for the treatment of retinal pathology, especially 
in SCD, but for SCD in general, a concept that we have since patented [74]. Perhaps 
equally as astounding is the fact that MMF delivered systemically induced such 
robust effects in retina, meaning that MMF must be capable of crossing in signifi-
cant quantities or otherwise inducing signaling across the blood-retinal barriers. 
Given the known difficulties with non-invasive yet efficacious drug delivery to the 
posterior segment of the eye (retina) and the commonality of oxidative stress and 
inflammation as key causative factors in the development and progression of numer-
ous retinal diseases, the clinical relevance and therefore potential impact of the above 
findings is extremely high. Indeed, new reports of potential benefit derived from 
MMF in animal models of the degenerative retinal disease continue to surface, such 
as the recent study by Jiang et al. [75] demonstrating that MMF treatment protects 
against light-induced retinal damage on BALB/C mice and effect due potentially to 
HCAR2-dependent signaling in retinal microglia cells (Figure 3). Eventually, data 
emanating from these preclinical reports may spur increased interest in moving 
toward clinical testing and implementation of FAE therapy in the near future.
4.8 Sepsis
Sepsis is a potentially fatal illness that can lead to the damage of multiple organs 
[76]. The condition is deeply associated with oxidative stress and inflammation. 
Firstly, a study by Giustina et al. [77] reported the protective effects of DMF 
against multi-organ sepsis by modulating oxidative stress and inflammation. It was 
reported that oral administration of 15 mg/kg of DMF provides significant protec-
tion against sepsis-induced multi-organ (heart, liver, and lung) damage in rats. 
Later, the same research group reported the protective effects of DMF treatment 
on sepsis-associated inflammation and oxidative stress and cognitive impairment 
in the brain [78]. Although both these studies were descriptive in nature as neither 
evaluated in detail the underlying mode of action, they provide evidence that DMF 
might be used successfully for the clinical management of sepsis. This is supported 
by a study by Shalmani et al. [79] in which it was reported that 50 mg/kg (i.p.) 
MMF treatment improved sepsis-induced liver dysfunction by regulating the 
TLR-4/NF-κB signaling pathway. Collectively, these preclinical studies provide a 
great foundation for future clinical evaluations of the utility of FAE in the manage-
ment of organ damage in sepsis.
4.9 Sickle cell disease-associated oxidative stress and inflammation
Uncontrolled hemolysis and subsequent release of hemoglobin (Hb) and heme 
into the vasculature is a hallmark of sickle cell disease (SCD) [80, 81]. Heme, a 
damage-associated molecular pattern, is highly pro-oxidative and proinflamma-
tory and induces vaso-occlusion in murine models of sickle cell disease (SCD) 
[82]. A study by Belcher et al. evaluated the protective effect of DMF treatment 
on SCD associated oxidative stress and inflammation in the liver and kidneys [83]. 
DMF (30 mg/kg/day) or vehicle (0.08% methylcellulose) was administered for 
3–7 days to NY1DD and HbSS-Townes SCD mice. DMF had a significant reduc-
tive impact on vaso-occlusion in SCD mice. It increased the nuclear translocation 
15
Repurposing Fumaric Acid Esters to Treat Conditions of Oxidative Stress and Inflammation:…
DOI: http://dx.doi.org/10.5772/intechopen.91915
of Nrf2 and cellular mRNA of Nrf2-responsive genes in livers and kidneys, and 
increased heme defenses, including HO-1, haptoglobin, hemopexin, and ferritin 
heavy chain, without altering plasma Hb and heme levels. Markers of inflammation 
were also reduced. Interestingly, much of the DMF-induced benefit was blunted by 
the HO-1 inhibitor, protoporphyrin. Chronic treatment (24 weeks) of SCD with 
DMF decreased hepatic necrosis, inflammatory cytokines, and irregularly shaped 
erythrocytes, and increased HbF but did not alter hematocrit, reticulocyte counts, 
lactate dehydrogenase or plasma heme levels or, spleen weights. These results [83] 
together with our previously highlighted findings in SCD (subSection 4.7) [34, 35], 
are supportive of the multiple beneficial effects of DMF/MMF on the pathogenesis 
of SCD and the need for further clinical evaluation of the drug for this indication.
4.10 Spinal cord injury
Patients with spinal cord injury (SCI) usually have permanent and often dev-
astating neurologic deficits and disabilities. The currently available therapeutic 
options include surgical decompression, methylprednisolone and hemodynamic 
control [84, 85]. Hence, the development of a new therapy for SCI holds great mer-
its. Recent work by Cordaro et al. [86] evaluated the beneficial effects of DMF and 
MMF in a mouse model of traumatic SCI. Using an aneurysm clip, SCI was induced 
by extradural compression of the spinal cord at T6-T7 for 1 min. Mice were then 
treated with 30 mg/kg (i.g) DMF or MMF one and 6 h post-SCI. To evaluate the 
locomotor activity, study mice were treated with DMF/MMF once daily for 10 days. 
It was observed that mice treated with DMF exhibited a significant and sustained 
recovery of motor function. DMF/MMF significantly reduced the severity of 
inflammation by modulation of pro-inflammatory cytokines and apoptosis factors 
and increased neurotrophic factors. The authors concluded that the observed results 
were attributable to reduced secondary inflammation and tissue injury and there-
fore, DMF may constitute a promising target for future SCI therapies [86]. This 
study provided the first scientific evidence for the protective role of DMF in the 
treatment of SCI, however, additional detailed experimental and preclinical studies 
are needed to identify the potential mechanism(s) of action and enhance the likeli-
hood that this therapy could be advanced to clinical testing and implementation.
4.11 Stroke
Over the past 2 years, researchers worldwide have published several articles on 
the role of FAE in the treatment of stroke. In one of the early studies on intrace-
rebral hemorrhage (ICH), male rats and mice (including Nrf2-deficient animals) 
were subjected to intracerebral injection of blood and then treated with DMF [87]. 
In rats, 5 mg/kg DMF was administered at 2 h post-ICH and again orally twice a 
day on days 1–3, whereas in mice, the same dose of DMF was injected (i.p.) 24 h 
post-ICH and then at days 2 and 3. Treatment with DMF induced Nrf2-target genes, 
improved hematoma resolution, reduced brain edema and eventually enhanced 
neurological recovery in rats and wild type mice, but not in Nrf2−/− mice. Based 
on these findings, the authors proposed that DMF may offer an impressive 24 h 
therapeutic window of opportunity in which to treat ICH, a concept certainly 
worthy of further evaluation. The potential of DMF/MMF therapy in ICH is sup-
ported further by work by Iniaghe et al. [88] in which male CD-1 mice were sub-
jected to intrastriatal infusion of bacterial collagenase, autologous blood or sham 
surgery. After ICH, animals either received vehicle, DMF (10 mg or 100 mg/kg) or 
casein kinase 2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl) acrylic acid (TBCA). 
Some mice also received scrambled siRNA or MAFG siRNA 24 h before ICH. DMF 
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treatment reduced Evans blue dye extravasation, decreased brain water content, 
microglia activation (Figure 3), ICAM-1 expression and, improved neurological 
deficits and casein kinase 2 levels. Interestingly, TBCA and MAFG siRNA blunted 
protection afforded by DMF. Hence, it was concluded that DMF reduced inflam-
mation, blood-brain barrier permeability, and improved neurological outcomes via 
casein kinase 2 and Nrf2 signaling pathways in mice.
Similar to other neurodegenerative disorders, oxidative stress is common also to 
the pathogenesis of ischemic stroke, potentiating the neuronal malfunction and cell 
death characteristic of this disease [89]. Given that the up-regulation of antioxidant 
genes through activation of the Nrf2 is one of the key mechanisms of cellular defense 
against oxidative stress [90], it is logical to explore the efficacy of FAE therapy in this 
condition. Congruent with this, three additional groups used experimental models 
of ischemic stroke to evaluate the efficacy of FAEs. In 2016, Lin et al. [91] observed 
that MMF (25–100 μM) rescued cultured cortical neurons from oxygen–glucose 
deprivation (OGD) and suppressed pro-inflammatory cytokines produced by 
primary mixed neuron/glia cultures subjected to OGD. In rats, DMF treatment (25 
or 50 mg/kg twice daily) significantly decreased infarction volume by nearly 40% 
and significantly improved neurobehavioral deficits after middle cerebral artery 
occlusion (MCAO). In the acute early phase (72 h after MCAO), DMF induced 
Nrf2 expression and its downstream mediator HO-1. In addition to its antioxidant 
role, DMF also acted as a potent immunomodulator, reducing the infiltration of 
neutrophils and T-cells as well as the number of activated microglia/ macrophages 
in the infarct region. Concomitantly, levels of pro-inflammatory cytokines were 
greatly reduced in the plasma and brain and oxygen–glucose deprived neuron/glia 
cultures. Further, using a mouse model of transient focal brain ischemia, Yao et al. 
[92] showed that DMF and MMF (30 mg/kg i.p.) significantly reduced neurological 
deficits, infarct volume, brain edema, and cell death. Additionally, DMF and MMF 
suppress glial activation following brain ischemia. Importantly, the protection of 
DMF and MMF was most evident during the sub-acute stage and was abolished in 
Nrf2−/− mice, indicating that the Nrf2 pathway is required for the beneficial effects 
of DMF and MMF [92]. In another study, murine organotypic hippocampal slice 
cultures, and two neuronal cell lines were treated with DMF and MMF [93]. The 
ischemic condition was generated by exposing cells and slice cultures to oxygen-glu-
cose deprivation. Treatment with both DMF and MMF (30–100 μM) immediately 
upon reoxygenation strongly reduced cell death in hippocampal cultures ex vivo. 
Both DMF and MMF promoted neuronal survival in HT-22 and SH-SY5Y cell lines 
exposed to ischemic stress. However, interestingly, DMF but not MMF activated the 
anti-oxidative Nrf2 pathway in neurons. Accordingly, the protective effect of DMF 
but not MMF was abrogated in the neurons of Nrf2-deficient mice. These results 
provide the basis for a new therapeutic approach to treat ischemic pathologies such 
as stroke using a drug that is already approved by US-FDA for clinical use.
5. Safety profile
By and large, the short-term safety profile for DMF in patients with RMS is 
highly favorable [44, 45] and long-term safety analyses from the ENDORSE study 
sustains a favorable benefit: risk ratio [94]. The most common adverse events 
observed in patients receiving DMF include flushing, gastrointestinal (GI) events 
(e.g., diarrhea, nausea, abdominal pain, and vomiting), proteinuria, and pruritus 
[44, 45]. Aspirin pretreatment has been shown to reduce DMF induced adverse GI 
events [95]. Additionally, the leukotriene-receptor antagonist montelukast has been 
shown to help as well [96]. Further, it has been observed that consuming a high fat 
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and high protein meal just before DMF administration may reduce GI and flushing 
side effects by delaying its intestinal absorption. Notably, the risk of lymphopenia 
is higher in adults older than 55 years, in those with lower baseline lymphocyte 
counts, and those switching from natalizumab [97]. Cases of multifocal leukoen-
cephalopathy (PML) following DMF treatment have also been reported [98–107]. 
Highly worthy of mention, however, is the fact that each of the affected patients 
detailed above had well-known pre-existing risk factors for PML including lympho-
cytopenia, sarcoidosis, cancer history, and/or prior efalizumab use. Thus, the nega-
tive effects of MMF treatment on PML should be interpreted very carefully. Like 
other pharmacological therapies, DMF/MMF treatment is associated with some side 
effects importantly however, advancements toward developing improved formula-
tions minimize these events without losing efficacy are already being realized. For 
example, Alkermes, Inc. has developed diroximel fumarate (DRF), also known 
as ALKS8700, a novel MMF prodrug. Importantly, this new formulation has been 
shown to yield bioequivalent levels of MMF at the cellular level when compared 
directly to DMF (Figure 1) [108] while interacting less with off-target proteins and 
therefore producing fewer unwanted side effects [109]. Indeed, interim findings 
from EVOLVE-MS-1 and EVOLVE-MS-2 which demonstrate that DRF has a favor-
able safety and efficacy profile and is well-tolerated in MS patients [108, 110].
6. Conclusions
Drug repurposing is a very viable therapeutic strategy [18]. Many agents 
approved for other uses already have been tested in humans, so detailed informa-
tion is available on their pharmacology, formulation and potential side effects. Since 
repurposing expands upon past innovative endeavors, hopeful new treatments 
could be prepared for clinical trials rapidly. Historically, pharmaceutical companies 
have achieved a number of successes via drug repositioning (e.g., for Viagra, tha-
lidomide, metformin, etc.). Based on the literature available, DMF/MMF has been 
shown to protect against a variety of diseases other than MS and psoriasis.
7. Future perspectives
FAE are perhaps most noted for the robust antioxidant effects that they elicit via 
Nrf2 induction. A number of additional (non-FAE based) Nrf2 inducing drugs have 
been developed and tested in experimental and clinical systems in recent years (e.g., 
resveratrol, sulforaphane, etc.) and several have been with considerable success 
with regard to potential for clinical development [111]. However, the multimodal 
actions of FAE make this emerging drug stand out among the rest. It is commonly 
said that oxidative stress and inflammation go hand-in-hand, meaning that one 
potentiates the other in somewhat of a cyclic manner. Thus, it can only be hoped 
that in turn, if one is suppressed then the other similarly complies. However, things 
are usually not that simple. In the case of FAE, there are two arms of action: one 
induces Nrf2 and the other interacts with the anti-inflammatory hydroxycarboxylic 
acid receptor (HCAR2 or HCA2; Figure 2). Thus, the compound has a direct impact 
on inflammation independent of its actions on oxidative stress. The fascinating 
thing about these two mechanistic arms, is that they appear to act simultaneously 
in many cell and tissue systems. This may explain why FAE has exceled in so many 
variable pathologic conditions. MMF through its interaction with HCAR2, which 
is expressed by primary immune cells and a multitude of accessory immune cells 
(i.e., those that initiate the immune response and those cells like retinal pigment 
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epithelial cells, for example, that aren’t truly “immune” cells but are capable just 
the same of secreting pro- and anti-inflammatory factors depending upon the 
stimulus), elicits a tremendous anti-inflammatory response. The combined Nrf2-
inducing and immune-modulatory properties of FAE have enabled this drug to be 
efficacious in a broad range of body systems. The evidence provided in this chapter 
alone demonstrates convincingly that the benefits of FAE have been realized in the 
central nervous system (brain and retina), the cardiovascular system, the digestive 
and/or gastrointestinal system, the immune system, the integumentary system and 
the renal system; this list continues to grow. Thus, the potential clinical impact of 
FAE therapy use is high and importantly extremely broad. It is acknowledged that as 
with virtually all pharmacologic agents, FAE therapy is not without adverse effects. 
Importantly, however, the effects are relatively mild and the benefit(s) indisputably 
outweigh the risks. As such, there is a prompt need for additional experimental and 
clinical studies to translate the information gleaned from exploratory trials of FAE 
therapy in various cell, tissue, and disease types into clinical use.
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